NUPR1 and plasma cell myeloma: Remarkably, we have previously shown that genetic inactivation of Nupr1 antagonizes the growth of pancreatic cancer [16,23], and other laboratories have also demonstrated that genetic inactivation of NUPR1 stops the growth of hepatocarcinoma [24], non-small lung cancer [25], cholangiocarcinoma [26], glioblastoma [27], multiple myeloma [28,29], and osteosarcoma [30], thereby supporting NUPR1 as a promising therapeutic target for the development of new therapies against cancers.